英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
dividedness查看　dividedness　在百度字典中的解释百度英翻中〔查看〕
dividedness查看　dividedness　在Google字典中的解释Google英翻中〔查看〕
dividedness查看　dividedness　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • How Libtayo Works for Non-Small-Cell Lung Cancer - WebMD
    Libtayo may also be used along with a platinum-based chemotherapy as an initial (first-line) treatment for advanced or metastatic NSCLC that does not have other targetable mutations of EGFR, ALK
  • Diagnosis and Treatment of ALK Positive NSCLC - PMC
    Shaw AT, Kim DW, Mehra R, et al Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer N Engl J Med 2014;370(13):1189–1197 doi: 10 1056 NEJMoa1311107 [PMC free article] [Google Scholar] 33 Friboulet L, Li N, Katayama R, et al The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer
  • Libtayo® (cemiplimab-rwlc) in Combination with Chemotherapy Approved by . . .
    Libtayo may be used alone as your first treatment when your lung cancer has not spread outside your chest (locally advanced lung cancer) and you cannot have surgery or chemotherapy with radiation, OR your lung cancer has spread to other areas of your body (metastatic lung cancer), AND your tumor tests positive for high "PD-L1", AND your tumor
  • What is LIBTAYO® (cemiplimab-rwlc) | Advanced NSCLC
    LIBTAYO (Lib-TIE-oh) is a prescription medicine used to treat adults with a type of lung cancer called non–small cell lung cancer (NSCLC) that has not spread outside your chest (locally advanced lung cancer) and you cannot have surgery or chemotherapy with radiation, or your lung cancer has spread to other areas of your body (metastatic lung
  • Cemiplimab (Libtayo) - NCBI Bookshelf - National Center for . . .
    CADTH recommends that Libtayo in combination with platinum-based chemotherapy be reimbursed by public drug plans for the first-line treatment of adults with non–small cell lung cancer (NSCLC) whose tumours have no EGFR, ALK, or ROS1 aberrations and is locally advanced where patients are not candidates for surgical resection or definitive chemoradiation, or for those with metastatic NSCLC, if
  • Anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung . . .
    INTRODUCTION Anaplastic lymphoma kinase (ALK) is a tyrosine kinase that can be aberrantly expressed in several tumor types In non-small cell lung cancer (NSCLC), chromosomal rearrangements involving the ALK gene loci on chromosome 2 are found in approximately 3 to 5 percent of NSCLC tumors [] The most common ALK rearrangement in NSCLC juxtaposes the 5' end of the echinoderm microtubule
  • Treatment of metastatic ALK-positive non-small cell lung cancer: real . . .
    Background: Rearrangement in anaplastic lymphoma kinase (ALK) occurs in 4-7% of non-small cell lung cancer (NSCLC) cases Despite improved survival with tyrosine kinase inhibitors (TKIs), treatment resistance remains challenging This retrospective study analyzed advanced ALK-positive NSCLC patients, focusing on clinical aspects, treatments, resistance, and outcomes
  • Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer
    The current recommended adjuvant treatment for patients with resected ALK-positive NSCLC is platinum-based combination chemotherapy 2–4,19 However, adjuvant chemotherapy is associated with only
  • Libtayo® (cemiplimab-rwlc) in Combination with Chemotherapy Approved by . . .
    Adults with a type of lung cancer called NSCLC: Libtayo may be used in combination with chemotherapy that contains a platinum medicine as your first treatment when your lung cancer has not spread
  • Targeting ALK Rearrangements in NSCLC: Current State of the Art
    Anaplastic lymphoma kinase (ALK) alterations in non-small cell lung cancer (NSCLC) can be effectively treated with a variety of ALK-targeted drugs Larkins E, Blumenthal GM, Chen H, He K, Agarwal R, Gieser G, et al FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non-Small Cell Lung Cancer Following Crizotinib Clin





中文字典-英文字典  2005-2009